Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Sutro Biopharma, Inc.NASDAQ: STRO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 30.6% from a year ago

Cash & equivalents stood at $73.68M at the end of Q1 FY2026, down 30.6% from a year earlier and up 26.8% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.

Context

  • Cash & equivalents amounted to 30.4% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -30.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$73.68M+26.8% QoQ
Last fiscal yearDec 2025
$58.13M-69.5% YoY
Year agoMar 2025
$106.23M-30.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.6%——
1 year-69.5%——
3-year CAGR+7.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
58.13M USD
Year-over-year change
-69.5%
4-year CAGR
+17.6%

Cash & Equivalents vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -30.6% is the 4th highest of 9, against a peer median of -41.0%.
  • Cash & equivalents amounts to 30.4% of total assets for STRO, versus a peer median of 47.5%.
STRO Competitors
Cash & Equivalents for STRO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DTILPrecision BioSciences, Inc.Mar 2026$99.37M USD+28.7%-16.4%69.1%
STTKShattuck Labs, Inc.Mar 2026$90.42M USD+48.5%+4.6%88.5%
STROSutro Biopharma, Inc.Mar 2026$73.68M USD-30.6%+7.1%30.4%
GUTSFractyl Health, Inc. Common StockMar 2026$63.17M USD+50.0%+18.3%63.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
KLRSKalaris Therapeutics IncMar 2026$34.43M USD-65.9%+217.7%31.4%
PLRXPliant Therapeutics, Inc.Mar 2026$22.19M USD-75.9%+10.5%11.0%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$20.96M USD-31.1%-36.1%19.8%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
Peer median (excluding STRO) —-41.0%+2.0%47.5%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents30.41M47.25M69.27M190.3M58.13M
Short-term Investments167.52M287.11M306.35M126.59M83.3M
Net Receivables12.45M7.12M36.08M8.62M3.98M
Inventory00000
Other Current Assets111.67M9.85M17.8M5.52M
Total Current Assets218.52M353.15M421.54M343.31M150.93M
Property, Plant & Equipment (Net)51.59M51.06M44.76M35.87M21.55M
Goodwill00000
Intangible Assets00000
Long-term Investments68.78M(32.02M)000
Tax Assets00000
Other Non-current Assets2.53M34.75M4.44M8.03M1.35M
Total Non-current Assets122.89M53.79M49.19M43.9M22.9M
Total Assets341.41M406.94M470.74M387.21M173.83M
Account Payables6.01M4.8M9.44M10.48M7.57M
Short-term Debt9.38M17.09M4.06M00
Tax Payables0015.17M18K0
Deferred Revenue5.5M16.76M20.67M69.78M10.56M
Other Current Liabilities11.42M11.64M18.58M16.91M17.56M
Total Current Liabilities41.74M66.55M93.75M131.89M75.13M
Long-term Debt15.74M3.77M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)089.89M202.49M193.35M221.56M
Other Non-current Liabilities146K119K1.69M1.69M1.69M
Total Non-current Liabilities47.11M123.35M227.34M210.71M231.15M
Total Liabilities88.84M189.9M321.09M342.61M306.28M
Common Stock46K58K61K83K9K
Retained Earnings(333.41M)(452.62M)(559.41M)(786.87M)(977.96M)
Accumulated OCI(314K)(618K)21K39K19K
Other Stockholders Equity00000
Minority Interest00000
Total Equity252.56M217.05M149.65M44.6M(132.45M)
Total Debt57.37M55.02M33.64M23.15M15.67M
Net Debt26.96M7.76M(35.63M)(167.15M)(42.46M)

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.